Can an arthritis drug save sight? small trial tests adalimumab for rare eye diseases

NCT ID NCT07348588

Ongoing Disease control Sponsor: Centro de Pesquisa Rubens Siqueira Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This pilot study tests whether adalimumab, an anti-inflammatory drug, can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants will receive three injections into the eye over four months. The main goal is to see if the treatment slows vision loss and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adalimumab (a drug that reduces inflammation) injected into the eye
What this could lead to: If it works, this could point toward a treatment that slows vision loss in certain inherited retinal diseases.
What could go wrong: This is a very early, small pilot study with only 30 people. It may not show clear benefit, and eye injections carry risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinal degeneration retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) RETINITIS PIGMENTOSA (RP)

Contacts and locations

Show contact details

Locations

Rubens Siqueira Research Center

São José do Rio Preto, São Paulo, 15010-100, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.